Islatravir Lenacapavir Combo: A Weekly HIV Pill in Trials

Islatravir Lenacapavir Combo: A Weekly HIV Pill in Trials

Two of the biggest names in HIV drug development just put their compounds in the same tablet. That's not a small thing. Merck's islatravir and Gilead's lenacapavir have each made headlines on their own in recent years, and now they're being tested together as a once-weekly pill for people already living with HIV.

What Islatravir and Lenacapavir Actually Are

These aren't new HIV drugs cobbled together from old ones. Islatravir is the first nucleoside reverse transcriptase translocation inhibitor, a drug class that interferes with an HIV enzyme in a different way than the older nucleoside and nucleotide reverse transcriptase inhibitors most patients are already familiar with. That distinction matters because it means islatravir isn't just a reformulation, it works through a genuinely different mechanism, which is part of why researchers are excited about it.

Lenacapavir, developed by Gilead, is the first HIV capsid inhibitor, targeting the protein shell that protects the virus's genetic material.It's already familiar to some patients in other forms. An injectable version given twice a year, sold as Sunlenca, was approved back in 2022 for people with multidrug-resistant HIV, and an injectable form used for prevention, sold as Yeztugo, was approved more recently for PrEP. The islatravir-lenacapavir combination pill is a new pairing, aimed specifically at treatment rather than prevention.

If you're newer to the antiretroviral landscape or want the basics on how HIV treatment history got here, it helps to first understand how HIV progresses through its stages and why suppressing the virus early matters so much.

What the ISLEND Trials Actually Found

The data comes from two Phase 3 trials, ISLEND-1 and ISLEND-2, presented at the 26th International AIDS Conference in Rio de Janeiro in mid-2026. The randomized, double-blind ISLEND-1 trial enrolled 607 participants who were already virally suppressed on Biktarvy, across more than 100 sites in the United States and ten other countries. That's a reasonably sized, geographically spread trial, which adds some weight to the findings, though it's still early relative to how long a drug typically needs to be tracked before wide approval.

Both ISLEND trials evaluated the safety and efficacy of a once-weekly single tablet combining islatravir and lenacapavir, and both showed high rates of virologic suppression sustained through week 48. In plain terms: people who switched from their existing daily pill to this weekly tablet largely stayed suppressed, meaning the virus stayed at very low, undetectable levels in their blood. That's the outcome doctors care about most, since it's tied directly to long-term health and to preventing transmission to partners. For readers who want a refresher on why that number matters clinically, our explainer on understanding HIV viral load breaks down what "suppressed" and "undetectable" actually mean in practice.

The trial population had a median age around 49, with roughly half of participants over 50 and 17% over 65, which researchers noted reflects the real-world demographics of people currently living with HIV. That's worth pointing out, because trial populations that actually resemble the patients who'll eventually use the drug tend to produce more clinically useful data than younger, healthier cohorts.

Why This Isn't Approved Yet

Here's the part that's easy to skim past in the excitement: islatravir and lenacapavir in combination are investigational and not yet approved for use by any regulatory authority.The ISLEND trial data is intended to form the basis of future regulatory submissions, not to confirm approval has already happened. The studies are also continuing to 96 weeks, so what's public now is really a strong midpoint checkpoint, not the final word.

In clinical practice, this is often the part patients misunderstand when they read trial headlines. A drug showing strong Phase 3 results is genuinely encouraging, but it still has to clear regulatory review, post-marketing safety monitoring, and often a period of real-world prescribing data before it becomes a standard option a doctor reaches for without hesitation.

How This Fits Into the Bigger Weekly-Dosing Trend

This combination isn't happening in isolation. Merck has also been testing islatravir alongside another compound, ulonivirine, as a separate once-weekly oral option, alongside its existing once-daily islatravir and doravirine pill, sold as Idvynso, which was already approved in the US earlier in That tells you something: the industry isn't betting on one weekly formula, it's exploring several, likely because no single combination will suit every patient's resistance history or tolerability profile.

Long-acting formulations have already changed care in other chronic conditions too. Mental health treatment offers a useful parallel, where long-acting injectables like Invega Sustenna were developed specifically to reduce the burden of daily pill-taking for patients who struggle with consistency. HIV treatment is following a similar logic, just later and for different biological reasons. Even therapies given as injections for other chronic illnesses, like Repatha for cholesterol, show how much the field values dosing schedules that fit around a person's actual life rather than the other way around.

Who Might Actually Use This, If Approved

Assuming regulatory approval eventually comes through, this combination would likely appeal most to people who are already virally suppressed on a stable daily regimen and simply want fewer dosing days. That was, notably, the exact population studied. It wasn't tested in people starting treatment for the first time or those with active drug resistance, so it's not yet clear how it would perform in those groups.

It's also worth being honest that not everyone wants to change something that's already working. If your current daily pill keeps you undetectable with no side effects, switching purely for convenience is a personal decision, not a medical requirement. That conversation belongs with your own HIV specialist, who knows your resistance history and treatment response far better than any article can.

What to Ask Your Doctor Right Now

Even though this combination isn't available for prescription yet, it's reasonable to bring it up at your next appointment, especially if daily dosing has been a genuine struggle. Ask whether your clinic is involved in any ongoing trials, how your current regimen compares in terms of resistance profile, and what your doctor expects the approval timeline to realistically look like. You can also search for an infectious disease specialist near you or use the DoctorBook specialist finder if you don't currently have one. Keeping tabs on your white blood cell counts and immune markers alongside these conversations gives your doctor a fuller picture of how well any regimen, current or future, is actually working for you.

It's also worth remembering that HIV care doesn't stop at the pill. Understanding HIV transmission risk and knowing the difference between HIV and other STDs remains relevant no matter what pill schedule you're on. Complications that can develop with long-term HIV, like HIV retinopathy affecting the eyes, are also worth monitoring regardless of dosing frequency. And because HIV comes in different strains and subtypes, your doctor will factor that into whether a newer regimen is a good fit for you specifically.

Broader sexual health habits still matter here too. Regular STI screening, understanding options like Medicare coverage for STI testing if applicable, being aware of common STDs in men, knowing what to do after condom breakage, and choosing safe lubricant products all remain part of a complete sexual health picture, separate from whatever pill schedule someone eventually ends up on. Reading more broadly about sexual health and wellbeing is a reasonable place to start if any of this feels new to you.

If you're not sure where to begin, a general doctor consultation is a fine first step before being referred to a specialist, and home visit doctor services exist for people who have trouble traveling to a clinic. If something feels urgent, like a fever that won't resolve, it's worth reading about when a fever needs specialist attention or simply locating a hospital near you.